News
TELA
0.6780
-5.86%
-0.0422
Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Sonida Senior Living (SNDA) and TELA Bio (TELA)
TipRanks · 2d ago
Analysts Are Bullish on Top Healthcare Stocks: Hims & Hers Health (HIMS), TELA Bio (TELA)
TipRanks · 2d ago
Piper Sandler Sticks to Its Hold Rating for TELA Bio (TELA)
TipRanks · 2d ago
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
NASDAQ · 3d ago
Tela Bio reports Q2 EPS (20c), consensus (18c)
TipRanks · 3d ago
Tela Bio withdraws FY26 guidance
TipRanks · 3d ago
TELA Bio GAAP EPS of -$0.20 misses by $0.03, revenue of $19.3M misses by $0.71M
Seeking Alpha · 3d ago
TELA Bio Q2 EPS $(0.20) Misses $(0.18) Estimate, Sales $19.291M Miss $20.008M Estimate
Benzinga · 3d ago
*TELA Bio 2Q Loss/Shr 20c >TELA
Dow Jones · 3d ago
*TELA Bio 2Q Loss $11.3M >TELA
Dow Jones · 3d ago
*TELA Bio 2Q Rev $19.3M >TELA
Dow Jones · 3d ago
Press Release: TELA Bio Reports Second Quarter 2026 Financial Results
Dow Jones · 3d ago
Weekly Report: what happened at TELA last week (0803-0807)?
Weekly Report · 3d ago
Lake Street Keeps Their Buy Rating on TELA Bio (TELA)
TipRanks · 08/04 14:19
Tela Bio appoints Heather Getz as CEO
TipRanks · 08/04 13:21
TELA Bio Names Heather Getz CEO
NASDAQ · 08/04 12:35
TELA Bio appoints Heather Getz as new CEO
TipRanks · 08/04 11:29
TELA Bio Appoints Heather Getz CEO, Effective Immediately
Benzinga · 08/04 11:11
Press Release: TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director
Dow Jones · 08/04 11:00
*TELA Bio Announces Appointment of Heather Getz as CEO and Director >TELA
Dow Jones · 08/04 11:00
More
Webull provides a variety of real-time TELA stock news. You can receive the latest news about Tela Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TELA
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.